Innovent Biologics ( ($HK:1801) ) has provided an update. Innovent Biologics announced that China’s National Medical Products Administration has ...

In locally recurrent rectal cancer, neoadjuvant chemo-reirradiation plus surgery with IOERT showed no grade 4–5 toxicities ...

At the San Antonio Breast Cancer Symposium, investigators reported findings from a retrospective study exploring whether ...

AstraZeneca and Daiichi Sankyo’s Enhertu's breakthrough therapy designation as a post-neoadjuvant treatment option for ...

Adjuvant carboplatin added to standard anthracycline/taxane chemotherapy significantly improves outcomes in early ...

Receiving neoadjuvant endocrine therapy enabled many postmenopausal patients with ER+, HER2- breast cancer to undergo breast-conserving surgery.

Hyperthermic Intraperitoneal Chemotherapy–Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer Immunohistochemistry-defined ER+, HER2– breast cancers, even when classified ...

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of ...